ArticleAmerican journal of respiratory and critical care medicine2021
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
Abstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Role of casual contact in drug-resistant tuberculosis transmission: a molecular epidemiology study.American journal of respiratory and critical care medicine · 2026Article
- Safety pharmacology and toxicology of a novel nitroimidazooxazole antitubercular agent in SD rat and Beagle dogs.Molecular biomedicine · 2026Article
- Draft genomes of three XDRMicrobiology resource announcements · 2026Article
- Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study.The Lancet regional health. Europe · 2025Article
- Transmission of tuberculosis in rural Henan, China: a prospective population-based genomic spatial epidemiological study.Emerging microbes & infections · 2024Article
- Article
- Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017-2022.Emerging infectious diseases · 2024Article
- Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.Emerging infectious diseases · 2024Article
- Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.BMC infectious diseases · 2024Article
- A multifaceted interplay between virulence, drug resistance, and the phylogeographic landscape ofMicrobiology spectrum · 2023Article
- Insight into pathogenomics and phylogeography of hypervirulent and highly-lethal Mycobacterium tuberculosis strain cluster.BMC infectious diseases · 2023Article
- Insight into Population Structure and Drug Resistance of Pediatric Tuberculosis Strains from China and Russia Gained through Whole-Genome Sequencing.International journal of molecular sciences · 2023Article
- Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.The Lancet. Infectious diseases · 2023Review
- Availability and costs of medicines for the treatment of tuberculosis in Europe.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Article
- Article
- Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.Emerging infectious diseases · 2022Article
- Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing.Genome medicine · 2022Article
- Accuracy of an amplicon-sequencing nanopore approach to identify variants in tuberculosis drug-resistance-associated genes.Microbial genomics · 2021Article
- The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2021Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 11 institutions in 11 countries.
Maroussia RoelensInstitute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-0876-4673
Giovanni Battista MiglioriIstituti Clinici Scientifici Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico, Tradate, Italy.
Liudmila RozanovaInstitute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Janne EstillInstitute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Jonathon R CampbellMcGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada.
J Peter CegielskiDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Simon TiberiBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Domingo PalmeroHospital F. J. Muñiz, Buenos Aires, Argentina.
Greg J FoxFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Lorenzo GuglielmettiÉquipe 13, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Unité 1135, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Giovanni SotgiuClinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
James C M BrustAlbert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
Didi BangStatens Serum Institut, Copenhagen, Denmark.
Christian LienhardtUnité Mixte Internationale TransVIHMI (Université de Montpellier, UMI 233 IRD, U1175 INSERM), Institut de Recherche pour le Développement, Montpellier, France.
Christoph LangeGerman Center for Infection Research Clinical Tuberculosis Center, Research Center Borstel, Borstel, Germany.
Dick MenziesMcGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada.
Olivia KeiserInstitute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Mario RaviglioneCentre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy.
University of Geneva · CHInserm · FRMcGill University Health Centre · CAAlbert Einstein College of Medicine · USBaylor College of Medicine · USEmory University · USHospital Muñiz · ARNational Health Service · GBStatens Serum Institut · DKThe University of Sydney · AUUniversity of Sassari · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntitubercular AgentsDatabases, FactualDiarylquinolinesDrug Administration ScheduleDrug Resistance, Multiple, BacterialDrug Therapy, CombinationExtensively Drug-Resistant TuberculosisFemaleFluoroquinolonesHumansIsoniazidLinezolidLogistic ModelsMaleAntitubercular AgentsbedaquilineDiarylquinolinesFluoroquinolonesIsoniazidLinezolidRifampindrug resistanceepidemiologymeta-analysistuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.